What records are connected here?
- Evidence lanes
- 3
- Source years
- 9
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsHormones · Bone and growth
Etelcalcetide is a synthetic peptide that activates the calcium-sensing receptor on the parathyroid glands, and the active ingredient in Parsabiv.1,2 FDA approved Parsabiv in 2017 for secondary hyperparathyroidism, overactive parathyroid glands caused by kidney failure, in adults on hemodialysis.1,2 In two randomized, placebo-controlled trials of more than 1,000 adults, about three in four on etelcalcetide cut parathyroid hormone by more than 30%, versus about one in ten on placebo. The label warns of low blood calcium.1
| What it is | A synthetic peptide calcimimetic: it binds the calcium-sensing receptor and makes it more responsive to calcium, which lowers parathyroid hormone release, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Parsabiv with an original approval date of February 7, 2017. The cited label has no boxed warning.1,2 |
| Human evidence | Two 26-week randomized, double-blind, placebo-controlled trials in 508 and 515 adults on hemodialysis, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Etelcalcetide is a synthetic peptide agonist of the calcium-sensing receptor, according to the label.1
In the United States it is the active ingredient of Parsabiv, approved under NDA 208325, according to Drugs@FDA.2
The label states that etelcalcetide binds the calcium-sensing receptor and enhances its activation by calcium in the blood. Activating this receptor on parathyroid cells lowers the release of parathyroid hormone (PTH).1
The label describes two 26-week randomized, double-blind, placebo-controlled trials in adults with secondary hyperparathyroidism on hemodialysis: Study 1 in 508 patients and Study 2 in 515.1
The main outcome was a more than 30% fall in PTH. It was reached by 77% on etelcalcetide versus 11% on placebo in Study 1, and 79% versus 11% in Study 2, according to the label.1
Blood calcium and phosphate also fell more with etelcalcetide than with placebo, according to the label.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Parsabiv, application NDA 208325, with an original approval date of February 7, 2017.2
The Parsabiv label cited here (DailyMed SPL version 15, published March 16, 2026) states that it is indicated for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, and that it has not been studied in people with kidney disease who are not on hemodialysis.1
The label has no boxed warning. Its warnings include low blood calcium, which can be severe, worsening heart failure, upper gastrointestinal bleeding, and adynamic bone disease if PTH is suppressed too long.1
Whether lowering PTH with it reduces fractures, heart problems or deaths: the label’s trials measured PTH, calcium and phosphate over 26 weeks.1
Its use in parathyroid cancer, primary hyperparathyroidism or kidney disease without hemodialysis, which the label states were not studied.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Etelcalcetide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Etelcalcetide are a bounded selection, not every registration or paper about Etelcalcetide. For the years before Etelcalcetide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Etelcalcetide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Etelcalcetide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Parsabiv for secondary hyperparathyroidism on hemodialysis. Two randomized, placebo-controlled trials of 508 and 515 adults described in the label found larger falls in parathyroid hormone with etelcalcetide. The label warns of low blood calcium.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Parsabiv for secondary hyperparathyroidism on hemodialysis. Two randomized, placebo-controlled trials of 508 and 515 adults described in the label found larger falls in parathyroid hormone with etelcalcetide. The label warns of low blood calcium.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 31, 2026
Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.↗Source date October 31, 2026Literature metadata · added November 15, 2026
Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.↗Source date October 12, 2026Literature metadata · added November 15, 2026
Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia.↗Source date October 12, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
17 of 17 selected trial records include at least one phase value; 17 of 17 include a status value in the retained structured contract.
28 of 28 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide.
28 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span February 7, 2017 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 36790677 in International urology and nephrology as Observational Study, Journal Article, with publication-date metadata of 2023-02-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 29691773 in PharmacoEconomics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-11 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42853437 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-09 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 28063122 in Journal of pharmacokinetics and pharmacodynamics as Journal Article, with publication-date metadata of 2017-01-06 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41307414 in Clinical nephrology as Journal Article, Observational Study, Clinical Trial, Phase IV, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42739661 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-08-28 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39557587 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Journal Article, Observational Study, Multicenter Study, with publication-date metadata of 2024-11-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03969329 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗
Literature metadata
PubMed lists PMID 39081745 in Kidney international reports as Journal Article, with publication-date metadata of 2024-04-04 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03633708 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗
Literature metadata
PubMed lists PMID 30013296 in P & T : a peer-reviewed journal for formulary management as Journal Article, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 29719376 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2018-04-19 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026